Treating diastolic dysfunction centers on lowering blood pressure, managing the conditions that drive it, and using a handful of medications that have shown measurable improvements in how the heart fills during its resting phase. There is no single pill that reverses the problem outright. Instead, treatment works on multiple fronts: reducing the stiffness and sluggish relaxation of the left ventricle, relieving fluid overload, and tackling the web of comorbidities that sustain the disease. The evidence base has expanded considerably in recent years, with newer drug classes and lifestyle strategies showing genuine promise.
What Goes Wrong in Diastolic Dysfunction
In a normally functioning heart, the left ventricle relaxes quickly after each beat and fills with blood at low pressure. In diastolic dysfunction, that relaxation slows down and the ventricle becomes stiffer, so it takes higher pressures to push blood in during the filling phase.1PubMed Central. Unmasking Left Ventricular Diastolic Dysfunction: Pathophysiology, Diagnosis, and Treatment Strategies Researchers have directly measured this in people with diastolic heart failure: the time it takes for the ventricle to relax is nearly twice as long as in healthy controls, and the passive stiffness of the chamber wall is roughly three times higher.2PubMed. Diastolic heart failure–abnormalities in active relaxation and passive stiffness of the left ventricle
At a cellular level, the stiffness traces back to changes in the heart’s structural scaffolding and its individual muscle cells. A giant spring-like protein called titin, which sits inside each heart muscle cell, becomes stiffer when it is modified by inflammation and reduced signaling from nitric oxide, a molecule that normally keeps blood vessels and heart tissue supple.3PubMed. Molecular and cellular basis for diastolic dysfunction Meanwhile, excess collagen builds up in the tissue between cells, adding another layer of rigidity. This is why treatment aims at both reducing inflammation and preventing fibrosis, not just managing symptoms.
Blood Pressure Control Is the Single Most Impactful Step
High blood pressure is the most common driver of diastolic dysfunction, and lowering it reliably improves how well the heart relaxes. In a randomized trial of 228 people with uncontrolled hypertension and documented diastolic dysfunction, both an intensive blood-pressure target (below 130 systolic) and a standard target (below 140 systolic) led to meaningful improvement in the speed of heart-muscle relaxation. The degree of improvement tracked closely with how much blood pressure actually came down: the lower the achieved pressure, the better the heart relaxed.4PubMed. Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction
Interestingly, it seems to be the blood pressure reduction itself that matters more than which drug achieves it. A separate trial using valsartan showed that relaxation improved in both the drug group and the placebo group, as long as blood pressure fell, and there was no significant difference between the two arms once the pressure drop was accounted for.5The Lancet. Effects of valsartan on morbidity and mortality in patients with chronic heart failure: the CHARM-Overall programme That said, ACE inhibitors and angiotensin receptor blockers are generally recommended as first-line choices for people with hypertension and diastolic dysfunction, because they may offer benefits beyond blood pressure alone, including reducing fibrosis. Beta-blockers, calcium channel blockers, and diuretics have also shown some ability to improve diastolic filling measures.6PubMed. Treatment of diastolic dysfunction in hypertension
Medications That Target Diastolic Function More Directly
Beyond standard blood-pressure drugs, several medication classes have emerged with evidence that they improve diastolic measures or reduce heart-failure events in people whose pumping function is preserved but whose filling function is impaired.
SGLT2 Inhibitors
Originally developed for diabetes, SGLT2 inhibitors (drugs like empagliflozin and dapagliflozin) have become one of the most important additions to heart-failure treatment in recent years. Trials have shown significant reductions in cardiovascular events not only in heart failure with reduced pumping function but also in heart failure with preserved ejection fraction, the form most closely associated with diastolic dysfunction.7PubMed Central. SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence The mechanisms are still being worked out, but these drugs appear to reduce fluid overload, lower filling pressures, and have direct effects on the heart muscle that go beyond their glucose-lowering action. They are now part of guideline-recommended therapy for heart failure with preserved ejection fraction.
Sacubitril/Valsartan
This combination drug pairs an angiotensin receptor blocker with a neprilysin inhibitor, which boosts levels of protective hormones that promote blood vessel relaxation and salt excretion. A meta-analysis pooling data from multiple trials found that sacubitril/valsartan significantly lowered filling pressures (as measured by the E/e’ ratio) and reduced left atrial size compared to control treatments.8PubMed Central. Evaluating the impact of Sacubitril/valsartan on diastolic function in patients with heart failure: A systematic review and meta-analysis In the PARABLE trial, people randomized to sacubitril/valsartan had fewer major cardiovascular events than those on valsartan alone, with an adjusted hazard ratio suggesting roughly a 60% relative reduction in the risk of a first major cardiovascular event.9JAMA Cardiology. Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre–Heart Failure With Preserved Ejection Fraction
Subgroup analyses from the large PARAGON-HF trial have suggested that certain populations benefit more, particularly women and people who were recently hospitalized for heart failure. The benefit also appeared greater in patients with ejection fractions below about 60%, which overlaps with what clinicians now call heart failure with mildly reduced ejection fraction.10Pharmacy Times. Sacubitiril/Valsartan Combination Shows Reduction in Hospitalizations in Women with Diastolic Heart Failure So while sacubitril/valsartan does improve diastolic parameters broadly, its clinical event benefit may be strongest in a subset of patients rather than across the entire spectrum of preserved-ejection-fraction heart failure.
Mineralocorticoid Receptor Antagonists
Spironolactone and eplerenone block the effects of aldosterone, a hormone that promotes fluid retention and the buildup of collagen in the heart muscle. By reducing fibrosis and extracellular matrix turnover, these drugs address one of the core structural problems in diastolic dysfunction.11PubMed Central. Role of spironolactone in the treatment of heart failure with preserved ejection fraction In one study, six months of spironolactone treatment led to significant improvements in tissue relaxation velocities. However, the overall grade of diastolic dysfunction did not change significantly, suggesting that the improvements were real but modest.12University Heart Journal. Effects of Spironolactone on Diastolic Function in Patients with Heart Failure with Preserved Ejection Fraction Both spironolactone and eplerenone also lowered levels of aldosterone and norepinephrine, neurohormones that drive disease progression.13Cardiovascular Therapy and Prevention. Effects of spironolactone and eplerenone on left ventricular diastolic function and neurohumoral factors in patients with heart failure
Exercise Training and Physical Activity
Exercise is one of the few interventions that consistently improves how people with diastolic dysfunction feel and function in daily life, even when the evidence on whether it fixes the underlying heart mechanics is mixed. In the Ex-DHF pilot study, patients with heart failure and preserved ejection fraction who did supervised endurance and resistance training for three months saw their peak oxygen consumption rise by about 2.6 mL/kg/min more than controls, alongside a meaningful drop in the E/e’ ratio, indicating lower filling pressures. The improvement in filling pressures accounted for a large share of the gain in exercise capacity.14PubMed. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study
A study of patients with chronic heart failure of mixed types found that after a structured exercise program, about 28% of participants improved by at least one diastolic dysfunction grade, and the group as a whole showed statistically significant improvement in diastolic grade distribution.15PubMed Central. Effects of exercise training on diastolic and systolic dysfunction in patients with chronic heart failure But the picture is not entirely clean. A more recent analysis using invasive measurements during exercise found that while cycling training clearly improved fitness in people with heart failure and preserved ejection fraction, it did not change filling pressures, relaxation time, or any measure of early diastolic function at rest or during submaximal exercise.16Circulation. Exercise Training Does Not Alter Early Diastolic Function in Patients with Heart Failure with Preserved Ejection Fraction
The practical takeaway is that exercise training reliably helps people do more with less breathlessness and fatigue, even if the mechanism is partly about improved peripheral fitness (better oxygen extraction by muscles, improved blood vessel function) rather than a direct rewiring of how the heart relaxes. For most people with diastolic dysfunction, that functional improvement is what matters most in daily life.
Dietary Changes and Sodium Restriction
A small but carefully designed study tested the DASH diet combined with sodium restriction in patients with hypertension and heart failure with preserved ejection fraction. After just three weeks, the diet significantly improved both ventricular relaxation and chamber stiffness, the two hallmark abnormalities of diastolic dysfunction. The coupling between the heart and the blood vessels also improved, meaning the heart was working more efficiently against the resistance of the circulation.17PubMed Central. Low-Sodium DASH Diet Improves Diastolic Function and Ventricular-Arterial Coupling in Hypertensive Heart Failure with Preserved Ejection Fraction This is one of the only dietary interventions that has been tested with quantitative diastolic-function measurements, and the results were striking for such a short intervention period. Reducing sodium intake lowers blood volume and afterload, which directly reduces the pressure the ventricle has to work against during filling. Combined with the potassium, magnesium, and fiber content of the DASH diet, this appears to address multiple contributors to diastolic dysfunction at once.
Weight Loss and GLP-1 Receptor Agonists
Obesity is now recognized as a central driver of a specific phenotype of heart failure with preserved ejection fraction, and weight loss has emerged as a potent treatment for this group. The STEP-HFpEF trial tested the GLP-1 receptor agonist semaglutide (the same drug used for weight management) in people with obesity-related heart failure and preserved ejection fraction. Semaglutide produced a meaningful improvement in symptoms, physical limitations, and six-minute walk distance, with a roughly 20-meter advantage over placebo in walking distance and nearly an 8-point advantage in a composite symptom score.18PubMed. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
The benefits held up across different levels of obesity and, in people with type 2 diabetes, across different levels of blood-sugar control.19PubMed. Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels A prespecified analysis of the trial found that the more weight a person lost on semaglutide, the greater the improvement in symptoms, exercise function, and inflammatory markers. For every 10% of body weight lost, symptom scores improved by about 6 points and walk distance by about 14 meters.20Nature Medicine. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial This dose-response relationship strongly suggests that the weight loss itself is doing much of the work. For people with diastolic dysfunction driven by obesity, aggressive weight management may be one of the most effective strategies available, whether achieved through medication, surgery, or sustained lifestyle change.
Why Diagnosis Matters for Treatment Selection
Diastolic dysfunction is graded by echocardiography, using a combination of blood flow patterns across the heart valves and tissue-movement velocities measured with Doppler imaging. No single measurement tells the whole story; a comprehensive assessment using multiple parameters is needed to avoid misclassification.21PubMed Central. Left ventricular diastolic function and dysfunction: Central role of echocardiography 22PubMed. Left Ventricular Diastolic Function: Understanding Pathophysiology, Diagnosis, and Prognosis With Echocardiography This matters because the grade of dysfunction and the estimated filling pressures guide treatment intensity. Someone with mild impaired relaxation and no symptoms might need only blood-pressure optimization and lifestyle changes. Someone with elevated filling pressures, an enlarged left atrium, and exercise intolerance likely needs the combination of medications described above plus close monitoring.
The gold-standard measurement remains invasive catheterization, where a pressure sensor is threaded into the left ventricle to directly measure relaxation time and chamber stiffness.23Journal of the American Society of Echocardiography. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography and for Heart Failure With Preserved Ejection Fraction Diagnosis This is rarely needed in routine care, but it becomes important when echocardiographic findings are ambiguous, when symptoms do not match the imaging, or when clinical decisions hinge on precise hemodynamic data.
When the Cause Is Something Specific
Not all diastolic dysfunction is driven by the usual suspects of hypertension, aging, obesity, and diabetes. Occasionally, diastolic dysfunction is the first clue to an infiltrative disease like cardiac amyloidosis, where abnormal proteins deposit in the heart wall and stiffen it. The echocardiographic pattern can look similar to garden-variety diastolic dysfunction, but clues like low-voltage electrical signals on an ECG paired with a thickened ventricle on imaging should prompt further investigation with blood tests and potentially a tissue biopsy. Treatment in this case is entirely different: it targets the source of the abnormal protein, such as chemotherapy for light-chain amyloidosis or newer drugs that stabilize the protein in transthyretin amyloidosis.24Medical Research Archives. Diastolic Dysfunction Unveiling Cardiac Light-Chain Amyloidosis: A Case Report Missing this diagnosis means treating the wrong disease, so clinicians should keep infiltrative causes in mind whenever diastolic dysfunction appears out of proportion to the usual risk factors.
Sex Differences in Diastolic Dysfunction
Heart failure with preserved ejection fraction, which is the symptomatic endpoint of progressive diastolic dysfunction, is considerably more common in women than in men and accounts for at least half of all heart-failure cases in women.25PubMed Central. Heart Failure in Women Postmenopausal women in particular have a higher prevalence and a somewhat distinct clinical profile compared to men with the same condition.26PubMed Central. Gender-Specific Differences in Diastolic Dysfunction and HFpEF: Pathophysiology, Diagnosis, and Therapeutic Strategies The reasons likely involve differences in how men’s and women’s hearts remodel in response to pressure overload, hormonal changes after menopause, and differences in comorbidity burden. There is also growing discussion about whether the diagnostic thresholds used on echocardiography should differ by sex, since normal values for cardiac structure vary between men and women.27PubMed. Sex Differences in Cardiovascular Pathophysiology: Why Women Are Overrepresented in Heart Failure With Preserved Ejection Fraction
Despite these differences in who gets the disease and why, current treatment guidelines do not recommend different medications for men versus women. Still, this is an area of active research, and some trial data hint that women may derive greater benefit from certain therapies like sacubitril/valsartan.
Catching It Early
Diastolic dysfunction is often found incidentally on an echocardiogram done for another reason. Many people with it have no symptoms at all, and there is a reasonable question about whether anything needs to be done at that stage. The evidence suggests yes: people with asymptomatic diastolic dysfunction are at elevated risk of progressing to symptomatic heart failure, and managing underlying conditions like hypertension, diabetes, and obesity at this point may delay or prevent that progression.28PubMed. Asymptomatic Left Ventricular Diastolic Dysfunction: Predicting Progression to Symptomatic Heart Failure This is not the same as starting heart-failure drugs in someone who feels fine. It means tightening blood pressure control, getting serious about weight management if needed, exercising regularly, and keeping a closer eye on cardiac imaging over time.
Device-Based and Monitoring Approaches
For people with more advanced disease who are in and out of the hospital despite optimal medications, two device-based strategies are under investigation or in clinical use. Implantable pulmonary artery pressure monitors allow clinicians to track heart-filling pressures remotely and adjust diuretics and other medications before congestion becomes severe enough to send someone to the emergency room. In both clinical trials and routine practice, this pressure-guided approach has been associated with lower rates of heart-failure hospitalization.29PubMed Central. Lower Rates of Heart Failure and All-Cause Hospitalizations During Pulmonary Artery Pressure-Guided Therapy for Ambulatory Heart Failure
A different concept involves creating a small opening between the left and right atria using a percutaneous device, essentially a controlled pressure-relief valve. When the left atrium’s pressure climbs too high (as it does in diastolic dysfunction), some blood shunts to the right side, lowering pressure in the lungs and reducing congestion.30PubMed Central. Device therapy with interatrial shunt devices for heart failure with preserved ejection fraction Several companies have developed versions of these interatrial shunt devices, and while early results have been mixed, they represent a fundamentally different approach to a disease that has historically had few targeted interventions.
The Comorbidity-Driven Model
One reason diastolic dysfunction has been so difficult to treat with a single drug is that it often is not one disease. A influential paradigm proposed that conditions like obesity, diabetes, hypertension, and chronic lung disease create a state of body-wide inflammation, which damages the lining of the tiny blood vessels inside the heart. That microvascular damage reduces nitric oxide signaling in neighboring heart muscle cells, leading to stiffened titin proteins and increased collagen deposition, the cellular changes that ultimately produce diastolic dysfunction.31Journal of the American College of Cardiology. A Novel Paradigm for Heart Failure With Preserved Ejection Fraction: Comorbidities Drive Myocardial Dysfunction and Remodeling Through Coronary Microvascular Endothelial Inflammation This framework explains why no single heart-failure drug has been a home run in clinical trials: if the disease is driven by five different comorbidities, you need to treat all five, not just the heart. It also explains why weight loss, exercise, blood-pressure control, and metabolic management each produce real but partial benefits. Effective treatment is less about finding the right pill and more about assembling the right combination of interventions for each person’s specific driver profile.